---
schema_version: "secwatch.filing_event.v1"
accession: "0001819790-23-000064"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2023-06-27T23:59:59+00:00"
generated_at: "2026-06-13T16:29:17.455173+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Tarsus shareholders elect three Class III directors, ratify E&Y as auditor

## Summary
- Andrew Goldberg, Scott Morrison, Wendy Yarno elected to board until 2026 annual meeting.
- Director election votes: Goldberg 16.18M for, Morrison 14.67M, Yarno 16.56M; each had 4.98M broker non-votes.
- Ratification of Ernst & Young as independent auditor for FY 2023 passed with 22.17M for, 7,065 against.
- Annual meeting held June 22, 2023; 22.18M of 26.80M shares represented a quorum.

## SEC filing metadata
- accession: 0001819790-23-000064
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2023-06-27T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000181979023000064/0001819790-23-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000181979023000064/tars-20230622.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001819790-23-000064
- JSON: https://secwatch.observer/filing/0001819790-23-000064.json
- Plain text: https://secwatch.observer/filing/0001819790-23-000064.txt

## Key facts
- Shareholder Votes
  Tarsus Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-22 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: Our stockholders approved the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000181979023000064/0001819790-23-000064-index.htm
- Shareholder Votes
  Tarsus Pharmaceuticals, Inc. shareholders approved Election of three nominees as Class III directors at the 2023-06-22 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: The following nominees were elected to serve as Class III directors for a term that will continue until the 2026 annual meeting of stockholders or until their respective successors have been duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000181979023000064/0001819790-23-000064-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.